Monday, August 29, 2022 10:36:29 PM
I understand your opinion, but I do not agree with your opinion. I believe that the FDA will quickly review and approve DCVax-L, once the BLA package is submitted, accepted and reviewed.
I take Dr. Pazdur at his word, when he said that the FDA wants to be the world leader in approving new safe and effective oncology treatments, especially those treatments that will become a new break-through treatment to meet an unmet need.
The FDA will have to approve DCVax-L for it to become a foundational part of the new standard of care (SOC) to treat ndGBM and rGBM patients worldwide.While a DCVax-L approval in the UK will be a very positive milestone, that country is too small on its own to justify making DCVax-L a part of the SOC to treat all GBM patients. The US / FDA will have to help make this happen.
I take Dr. Pazdur at his word, when he said that the FDA wants to be the world leader in approving new safe and effective oncology treatments, especially those treatments that will become a new break-through treatment to meet an unmet need.
The FDA will have to approve DCVax-L for it to become a foundational part of the new standard of care (SOC) to treat ndGBM and rGBM patients worldwide.While a DCVax-L approval in the UK will be a very positive milestone, that country is too small on its own to justify making DCVax-L a part of the SOC to treat all GBM patients. The US / FDA will have to help make this happen.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
